← Leaderboards
Krishna K Murthy
Southwest Foundation For Biomedical Res
$1,458,914
Attributed
$1,458,914
Total exposure
23
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $487.6K · FY2008–11$500K$375K$250K$125K$0
'08
'09
'10
'11
Funding mix
By agency
NIH$1,458,914 · 23
By mechanism
P51$1,168,914 · 21
N01$290,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesGrantUnited States National Institutes Of HealthSourceFundingInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelPan GenusInfectionVirusVaccinesAnimalsPapioHepatitis C VirusInfection PreventionPrimatesDoseAcquired Immunodeficiency SyndromeVaccinatedT-LymphocyteImmunogenicityPan TroglodytesImmune Response
Grant awards (23)
PRECLINICAL SAFETY AND IMMUNOGENICITY OF CONTREVIR IN CHIMPANZEES$208,272
P51 · FY2011 · RR · contact PI
GENE THERAPY USING INTRA-HEPATIC METHODGENE THERAPY INTRA-HEPATIC METHOD$128,825
P51 · FY2011 · RR · contact PI
A NOVEL STRATEGY TO INDUCE NEUTRALIZING ANTIBODIES TO HIV$25,423
P51 · FY2011 · RR · contact PI
GENE THERAPY USING INTRA-HEPATIC METHODGENE THERAPY INTRA-HEPATIC METHOD$148,173
P51 · FY2010 · RR · contact PI
INFECTIVITY AND PATHOGENESIS OF TISSUE CULTURE DERIVED HCV IN CHIMPANZEES$67,157
P51 · FY2010 · RR · contact PI
IMMUNOGENICITY AND EFFICACY OF A NOVEL CANDIDATE VACCINE FOR AIDS$15,990
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$206,898
P51 · FY2009 · RR · contact PI
TOXICITY AND SAFETY STUDY OF DB4C7 ANTIBODY IN BABOONS$185,317
P51 · FY2009 · RR · contact PI
INFECTIVITY AND PATHOGENESIS OF TISSUE CULTURE DERIVED HCV IN CHIMPANZEES$46,681
P51 · FY2009 · RR · contact PI
NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS$37,143
P51 · FY2009 · RR · contact PI
IMMUNOGENICITY AND EFFICACY OF A NOVEL CANDIDATE VACCINE FOR AIDS$11,553
P51 · FY2009 · RR · contact PI
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$23,282
P51 · FY2008 · RR · contact PI
RESTORING HCV-SPECIFIC T CELL FUNCTIONS IN CHRONIC HEPATITIS C$14,972
P51 · FY2008 · RR · contact PI
IMMUNOGENETHERAPY OF CHRONIC HCV CARRIER CHIMPANZEES$14,972
P51 · FY2008 · RR · contact PI
IMMUNOGENICITY OF HIV CANDIDATE VACCINES IN BABOONS$11,292
P51 · FY2008 · RR · contact PI
TOXICITY AND SAFETY STUDY OF DB4C7 ANTIBODY IN BABOONS$9,452
P51 · FY2008 · RR · contact PI
IMMUNOGENICITY AND EFFICACY OF A NOVEL CANDIDATE VACCINE FOR AIDS$5,836
P51 · FY2008 · RR · contact PI
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$3,743
P51 · FY2008 · RR · contact PI
HCV NUCLEIC ACID VACCINE STUDIES IN CHIMPANZEES$1,713
P51 · FY2008 · RR · contact PI
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$1,649
P51 · FY2008 · RR · contact PI
NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS$571
P51 · FY2008 · RR · contact PI
MAINTENANCE OF ANIMALS FOR HEPATITIS/AIDS RESEARCH$290,000
N01 · FY2000 · HB
HIV-1 RESEARCH &SPECIMEN PROCESSING IN CHIMPANZEES$0
N01 · FY2000 · AI